



27 November 2024

ASX Announcement

Island (ASX: ILA) investor webinar invitation

MELBOURNE Australia, 27 November 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to invite investors to an online briefing session on Wednesday, 27 November 2024, at 11.00am AEDT.

During this briefing, Island CEO and Managing Director, Dr David Foster, will discuss the positive Safety Review Committee findings from the Phase 2a component of Island's Phase 2a/b clinical trial in dengue fever (announced earlier today). The presentation will then be followed by a Q&A session.

To attend the webinar, please pre-register via the following link:
https://us02web.zoom.us/webinar/register/WN_i9QuJWg-QM-BSytHAtE4QA

To subscribe to Island's monthly newsletter, [IslandWatch](#), and other forms of email communications, please visit [this page](#) of our website.

Approved for release to the ASX by:

David Foster (CEO and Managing Director)
Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and



sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.